Assesses R&D returns of UK pharmaceutical companies to appraise IRR relative to WACC, as well as quantifying key drivers of value.
Joint Deloitte/ Thomson Reuters study, November 2011 | 16 pages
Stay connected:
Material on this website is © 2012 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see About Deloitte for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.
Life Sciences and Health Care
Life sciences and health care companies are experiencing a period of unprecedented change. Driven by shifts in age and demographics, disease, the entry of new technologies, increased and changing government regulations, and the pace of health care inflation, these companies will have to dramatically respond change in order to cope with the future environment.
Consumers of health care services want safer, better connected and more effective health care systems. Healthcare providers are responding in an environment where costs are increasing and skills are scarce.
Deloitte is helping public and private sector organisations respond to these and other issues to develop strategies that equip them for a successful future.
